688068 热景生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-2.794-5.9290.86330.580121.897
总资产报酬率 ROA (%)-2.557-5.5380.77425.04696.133
投入资产回报率 ROIC (%)-2.748-5.8740.84428.652111.849

边际利润分析
销售毛利率 (%)56.17955.36057.12753.71159.538
营业利润率 (%)-44.503-36.3263.41230.67248.134
息税前利润/营业总收入 (%)-49.985-42.941-5.07429.29048.151
净利润/营业总收入 (%)-41.670-38.3523.05126.01241.019

收益指标分析
经营活动净收益/利润总额(%)74.85353.547-302.162117.095102.716
价值变动净收益/利润总额(%)29.0284.984-157.9721.0150.964
营业外收支净额/利润总额(%)0.5201.216-24.724-1.454-0.101

偿债能力分析
流动比率 (X)4.5025.4794.4673.5173.429
速动比率 (X)4.2335.1253.7373.2153.077
资产负债率 (%)9.5787.5705.75613.99221.154
带息债务/全部投入资本 (%)2.2870.0350.7562.1538.587
股东权益/带息债务 (%)4,252.498287,930.29613,052.2494,497.7711,050.889
股东权益/负债合计 (%)945.0931,221.5811,638.419611.307368.803
利息保障倍数 (X)9.5236.9620.650-31.106738.811

营运能力分析
应收账款周转天数 (天)85.75742.15740.6046.7272.139
存货周转天数 (天)164.310174.159223.36745.14231.893